BPC 157 for athletes and injury treatment: Science, safety, and legal concerns BPC 157 FDA Approval Unlikely Due to Patent Economics Stefano M. Sinicropi, MD posted on the topic LinkedIn The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: The Body Protection Compound Revolutionizing Regenerative Medicine 503Pharma The Peptide Craze Ground Truths